Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2018

View Archived Issues

Vertex studies VX-659 triple combination in phase III cystic fibrosis study

Nektar initiates phase I/II study of NKTR-262 alone and in combination for solid tumor malignancies

AbbVie opens phase I trial of ABBV-744 in advanced prostate cancer and AML

Male contraceptive 11beta-MNTDC reduces testosterone in healthy male volunteers

Phase III efficacy and safety data reported for vibegron in overactive bladder

Phase III trials of rimegepant in migraine meet coprimary endpoints

Allecra reports phase II data on cefepime/AAI-101 in cUTI

Protagonist stops phase IIb study of PTG-100 for ulcerative colitis based on futility analysis

FDA grants breakthrough therapy designation to enfortumab vedotin

Loxo completes rolling NDA for larotrectinib in U.S.

Amag submits NDA for bremelanotide for hypoactive sexual desire disorder

EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1

Acorda submits MAA to EMA for Inbrija

EMA committee recommends approval of new dosing schedules for Opdivo in E.U.

Celgene tests new purine-based compound with antimalarial properties

FORMA Therapeutics establishes collaboration with Arpeggio Biosciences

Sanofi seeks U.S. and E.U. approval for sotagliflozin in type 1 diabetes

Vitaros end-of-review meeting scheduled by FDA

Japanese approval for Orkedia

Hemlibra approved in Japan

Hernicore approved in Japan to treat lumbar disc herniation

Bayer Pharma divluges new adenosine receptor A2B antagonists

Nippon Kayaku obtains Japanese approval for trastuzumab biosimilar

Jiangsu Hengrui Medicine Co., Shanghai Hengrui Pharmaceutical Co. patent factor XIa inhibitors

AdPueriVitam discovers novel NMDA receptor antagonists

Velcade approved in Japan for primary macroglobulinemia and lymphoplasmacytic lymphoma

Gilead identifies novel Toll-like receptor 8 modulators

RaQualia receives milestone payment from EA Pharma

New Toll-like receptor 7/8 agonists patented by GlaxoSmithKline

ACT-539313 safe and well tolerated in first-in-human study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...